Janus Henderson Group PLC Has $6.29 Million Holdings in Liquidia Co. (NASDAQ:LQDA)

Janus Henderson Group PLC boosted its position in Liquidia Co. (NASDAQ:LQDA - Free Report) by 1,484.5% during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 535,552 shares of the company's stock after buying an additional 501,752 shares during the quarter. Janus Henderson Group PLC owned approximately 0.63% of Liquidia worth $6,293,000 as of its most recent filing with the SEC.

A number of other hedge funds and other institutional investors have also bought and sold shares of LQDA. Corebridge Financial Inc. increased its position in shares of Liquidia by 2.3% during the 4th quarter. Corebridge Financial Inc. now owns 31,516 shares of the company's stock worth $371,000 after purchasing an additional 694 shares during the last quarter. Catalina Capital Group LLC increased its position in shares of Liquidia by 6.5% during the 4th quarter. Catalina Capital Group LLC now owns 18,307 shares of the company's stock worth $215,000 after purchasing an additional 1,125 shares during the last quarter. Cetera Investment Advisers increased its position in shares of Liquidia by 4.3% during the 4th quarter. Cetera Investment Advisers now owns 31,243 shares of the company's stock worth $367,000 after purchasing an additional 1,277 shares during the last quarter. Summit Investment Advisors Inc. increased its position in shares of Liquidia by 35.0% during the 4th quarter. Summit Investment Advisors Inc. now owns 6,632 shares of the company's stock worth $78,000 after purchasing an additional 1,719 shares during the last quarter. Finally, Sigma Planning Corp increased its position in shares of Liquidia by 3.4% during the 4th quarter. Sigma Planning Corp now owns 65,210 shares of the company's stock worth $767,000 after purchasing an additional 2,115 shares during the last quarter. Institutional investors and hedge funds own 64.54% of the company's stock.

Liquidia Price Performance

LQDA traded down $0.21 during trading on Friday, hitting $15.35. The stock had a trading volume of 4,742,122 shares, compared to its average volume of 1,065,159. The company has a 50 day moving average price of $14.74 and a 200-day moving average price of $13.57. The firm has a market cap of $1.31 billion, a price-to-earnings ratio of -9.42 and a beta of 0.24. Liquidia Co. has a one year low of $8.26 and a one year high of $19.41.

Liquidia (NASDAQ:LQDA - Get Free Report) last released its quarterly earnings results on Thursday, May 8th. The company reported ($0.45) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.42) by ($0.03). The firm had revenue of $3.12 million during the quarter, compared to the consensus estimate of $3.23 million. Liquidia had a negative net margin of 765.38% and a negative return on equity of 163.21%. As a group, sell-side analysts predict that Liquidia Co. will post -1.51 EPS for the current fiscal year.

Insider Activity at Liquidia

In other news, CEO Roger Jeffs sold 14,130 shares of the company's stock in a transaction on Monday, April 14th. The stock was sold at an average price of $13.57, for a total transaction of $191,744.10. Following the completion of the sale, the chief executive officer now directly owns 1,006,420 shares in the company, valued at approximately $13,657,119.40. This represents a 1.38% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, General Counsel Russell Schundler sold 5,964 shares of the company's stock in a transaction on Monday, April 14th. The shares were sold at an average price of $13.57, for a total value of $80,931.48. Following the sale, the general counsel now owns 570,301 shares of the company's stock, valued at approximately $7,738,984.57. The trade was a 1.03% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 33,138 shares of company stock worth $450,233 in the last ninety days. 26.50% of the stock is owned by company insiders.

Analyst Upgrades and Downgrades

Several research firms have weighed in on LQDA. Oppenheimer set a $13.00 price target on Liquidia and gave the stock an "underperform" rating in a research report on Monday. HC Wainwright reaffirmed a "buy" rating and set a $29.00 price target on shares of Liquidia in a research report on Monday, May 12th. Wall Street Zen raised Liquidia from a "sell" rating to a "hold" rating in a report on Thursday. Needham & Company LLC reissued a "buy" rating and set a $25.00 target price on shares of Liquidia in a report on Wednesday. Finally, Raymond James boosted their target price on Liquidia from $27.00 to $29.00 and gave the stock a "strong-buy" rating in a report on Friday, May 9th. One analyst has rated the stock with a sell rating, one has issued a hold rating, six have given a buy rating and two have assigned a strong buy rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of "Moderate Buy" and an average price target of $25.56.

Liquidia Company Profile

Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its lead product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD).